Literature DB >> 18794390

Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures.

Michael R Zile1, Tom D Bennett, Martin St John Sutton, Yong K Cho, Philip B Adamson, Mark F Aaron, Juan M Aranda, William T Abraham, Frank W Smart, Lynne Warner Stevenson, Fred J Kueffer, Robert C Bourge.   

Abstract

BACKGROUND: Approximately half of all patients with chronic heart failure (HF) have a decreased ejection fraction (EF) (systolic HF [SHF]); the other half have HF with a normal EF (diastolic HF [DHF]). However, the underlying pathophysiological differences between DHF and SHF patients are incompletely defined. The purpose of this study was to use echocardiographic and implantable hemodynamic monitor data to examine the pathophysiology of chronic compensated and acute decompensated HF in SHF versus DHF patients. METHODS AND
RESULTS: Patients were divided into 2 subgroups: 204 had EF <50% (SHF) and 70 had EF >or=50% (DHF). DHF patients had EF of 58+/-8%, end-diastolic dimension of 50+/-10 mm, estimated resting pulmonary artery diastolic pressure (ePAD) of 16+/-9 mm Hg, and diastolic distensibility index (ratio of ePAD to end-diastolic volume) of 0.11+/-0.06 mm Hg/mL. In contrast, SHF patients had EF of 24+/-10%, end-diastolic dimension of 68+/-11 mm, ePAD of 18+/-7 mm Hg, and diastolic distensibility index of 0.06+/-0.04 mm Hg/mL (P<0.05 versus DHF for all variables except ePAD). In SHF and DHF patients who developed acute decompensated HF, these events were associated with a significant increase in ePAD, from 17+/-7 to 22+/-7 mm Hg (P<0.05) in DHF and from 21+/-9 to 24+/-8 mm Hg (P<0.05) in SHF. As a group, patients who did not have acute decompensated HF events had no significant changes in ePAD.
CONCLUSIONS: Significant structural and functional differences were found between patients with SHF and those with DHF; however, elevated diastolic pressures play a pivotal role in the underlying pathophysiology of chronic compensated and acute decompensated HF in both SHF and DHF.

Entities:  

Mesh:

Year:  2008        PMID: 18794390     DOI: 10.1161/CIRCULATIONAHA.108.783910

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  138 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

2.  Congestion is the driving force behind heart failure.

Authors:  Maya Guglin
Journal:  Curr Heart Fail Rep       Date:  2012-09

3.  Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care.

Authors:  Stephen J Greene; G Michael Felker; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-11-05       Impact factor: 15.534

Review 4.  The vulnerable phase after hospitalization for heart failure.

Authors:  Stephen J Greene; Gregg C Fonarow; Muthiah Vaduganathan; Sadiya S Khan; Javed Butler; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

Review 5.  Treatment strategies for the prevention of heart failure.

Authors:  Justin L Grodin; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 6.  New insights into combinational drug therapy to manage congestion in heart failure.

Authors:  Frederik Hendrik Verbrugge; Lars Grieten; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-03

Review 7.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

8.  Timing and duration of interventions in clinical trials for patients with hospitalized heart failure.

Authors:  Catherine N Marti; Gregg C Fonarow; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-09-01       Impact factor: 8.790

Review 9.  Implantable devices to monitor patients with heart failure.

Authors:  Nikolaos Karamichalakis; John Parissis; George Bakosis; Vasiliki Bistola; Ignatios Ikonomidis; Antonios Sideris; Gerasimos Filippatos
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

10.  LV-MEMS: A New Challenger Against the CHAMPION?

Authors:  Kiyotake Ishikawa
Journal:  Circ Cardiovasc Interv       Date:  2018-05       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.